Phase 3 #SymptomScience @nejm.org RCT of elinzanetant vs placebo for moderate-to-severe vasomotor symptoms in HR+ #breast cancer (n=474) @ascocancer.bsky.social @cancercaremascc.bsky.social @hoperugo.bsky.social @coffeemommy.bsky.social @stage4kelly.bsky.social www.nejm.org/doi/full/10....